World Federation of Hemophilia / Fédération mondiale de l'hémophilie/LinkedIn
Oct 18, 2025, 11:15
Gene Therapy Data at Risk – WFH Advocates for Global Preservation Through GTR
World Federation of Hemophilia / Fédération mondiale de l’hémophilie posted on LinkedIn:
” Nearly 400 people with hemophilia joined Gene Therapy trials, sharing their data to help future generations. If companies do not commit to preserve Gene Therapy data in one global database, that data becomes far less useful. The WFH Gene Therapy Registry (GTR) offers a global solution to safeguard this data and honor those contributions.
Read more about why data preservation is both a scientific and ethical imperative.”
Stay updated with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis